- What is FutuRx's primary investment focus?
- FutuRx is an incubator dedicated to the inception of early-stage biopharma ventures based on cutting-edge science, supporting them in successful drug development. Their portfolio is entirely concentrated in the Health Tech & Life Sciences sector.
- Which organizations founded FutuRx?
- FutuRx was founded by Johnson & Johnson Innovation – JJDC, Takeda Pharmaceutical Company (through Takeda Ventures Inc.-TVI), OrbiMed Israel Partners, and the Israeli Innovation Authority of the Ministry of Economy. Leaps by Bayer later joined as an impact investment unit.
- What investment stages does FutuRx typically target?
- FutuRx primarily targets Pre-Seed, Seed, and A Round investments. According to startupim data, they have made 15 Seed investments and 1 Pre-Seed investment.
- Can you name some notable companies in FutuRx's portfolio?
- FutuRx has invested in companies such as BiomX, which focuses on microbiome therapies for chronic diseases, and Mitoconix Bio, which develops therapeutics for neurodegenerative diseases.
- Has FutuRx had any notable exits?
- Yes, FutuRx had an exit in November 2019 when BiomX completed a reverse merger with Chardan Healthcare Acquisition Corp and went public on the NYSE.
- What is the typical check size for FutuRx's investments?
- FutuRx's investment range for disclosed rounds is between $2.7 million and $3.6 million.
- Who is the CEO of FutuRx?
- Lianna Patt serves as the CEO of FutuRx.
- Where is FutuRx headquartered?
- FutuRx is headquartered in Ness Ziona, Israel.